A share price of FibroBiologics Inc [FBLG] is currently trading at $1.02, up 22.67%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The FBLG shares have gain 20.54% over the last week, with a monthly amount glided 6.57%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
FibroBiologics Inc [NASDAQ: FBLG] stock has seen the most recent analyst activity on December 12, 2024, when Rodman & Renshaw initiated its Buy rating and assigned the stock a price target of $12. Previously, H.C. Wainwright started tracking the stock with Buy rating on October 30, 2024, and set its price target to $12. On September 24, 2024, Maxim Group initiated with a Buy rating and assigned a price target of $12 on the stock.
FibroBiologics Inc experienced fluctuations in its stock price throughout the past year between $0.76 and $13.59. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. FibroBiologics Inc [NASDAQ: FBLG] shares were valued at $1.02 at the most recent close of the market. An investor can expect a potential return of 782.35% based on the average FBLG price forecast.
Analyzing the FBLG fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.67, Equity is -5.64 and Total Capital is -4.61. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.54.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.8434 points at the first support level, and at 0.6668 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.1633, and for the 2nd resistance point, it is at 1.3066.
Ratios To Look Out For
To put it in perspective, the Current Ratio for FibroBiologics Inc [NASDAQ:FBLG] is 1.14. Also, the Quick Ratio is 1.14, while the Cash Ratio stands at 1.06.
Transactions by insiders
Recent insider trading involved O’HEERON PETE, Chief Executive Officer, that happened on Aug 12 ’24 when 8500.0 shares were purchased. Chief Scientific Officer, Khoja Hamid completed a deal on Aug 12 ’24 to buy 10000.0 shares.
